KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Other (2016 - 2024)

CRISPR Therapeutics AG (CRSP) has disclosed Receivables - Other for 9 consecutive years, with $2.1 million as the latest value for Q4 2024.

  • Quarterly Receivables - Other fell 67.69% to $2.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2024, down 67.69% year-over-year, with the annual reading at $2.1 million for FY2024, 67.69% down from the prior year.
  • Receivables - Other hit $2.1 million in Q4 2024 for CRISPR Therapeutics AG, down from $6.5 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $25.0 million in Q1 2020 to a low of $2.1 million in Q4 2024.
  • Historically, Receivables - Other has averaged $14.2 million across 5 years, with a median of $11.0 million in 2020.
  • Biggest five-year swings in Receivables - Other: surged 7688.16% in 2020 and later plummeted 67.69% in 2024.
  • Year by year, Receivables - Other stood at $10.7 million in 2020, then dropped by 21.5% to $8.4 million in 2021, then skyrocketed by 33.33% to $11.2 million in 2022, then plummeted by 41.96% to $6.5 million in 2023, then tumbled by 67.69% to $2.1 million in 2024.
  • Business Quant data shows Receivables - Other for CRSP at $2.1 million in Q4 2024, $6.5 million in Q4 2023, and $11.2 million in Q4 2022.